Citius Pharmaceuticals Inc. (NASDAQ: CTXR) stock fell -0.09% on Friday to $0.76 against a previous-day closing price of $0.76. With 1.13 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.52 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.7957 whereas the lowest price it dropped to was $0.7575. The 52-week range on CTXR shows that it touched its highest point at $1.71 and its lowest point at $0.72 during that stretch. It currently has a 1-year price target of $5.33. Beta for the stock currently stands at 1.41.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CTXR was down-trending over the past week, with a drop of -14.25%, but this was down by -12.60% over a month. Three-month performance dropped to -39.75% while six-month performance fell -27.70%. The stock lost -38.28% in the past year, while it has lost -3.91% so far this year. A look at the trailing 12-month EPS for CTXR yields -0.21 with Next year EPS estimates of 0.73. For the next quarter, that number is -0.02. This implies an EPS growth rate of -2.10% for this year and 556.20% for next year.
Float and Shares Shorts:
At present, 153.78 million CTXR shares are outstanding with a float of 146.55 million shares on hand for trading. On Aug 30, 2023, short shares totaled 19.64 million, which was 12.36% higher than short shares on Jul 30, 2023. In addition to Mr. Leonard L. Mazur as the firm’s Co-Founder, CEO, Chairman & Sec., Mr. Myron Z. Holubiak serves as its Co-Founder & Exec. Vice Chairman.
Through their ownership of 10.67% of CTXR’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 9.68% of CTXR, in contrast to 7.75% held by mutual funds. Shares owned by individuals account for 6.26%. As the largest shareholder in CTXR with 4.69% of the stake, BlackRock Fund Advisors holds 7,456,909 shares worth 7,456,909. A second-largest stockholder of CTXR, The Vanguard Group, Inc., holds 6,564,131 shares, controlling over 4.13% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in CTXR, holding 2,608,033 shares or 1.64% stake. With a 2.60% stake in CTXR, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 4,132,683 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 1.71% of CTXR stock, is the second-largest Mutual Fund holder. It holds 2,714,812 shares valued at 2.48 million. Vanguard Extended Market Index Fu holds 1.21% of the stake in CTXR, owning 1,925,707 shares worth 1.76 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, CTXR reported revenue of $0.00 and operating income of -$8.92M. The EBITDA in the recently reported quarter was -$8.82M and diluted EPS was -$0.06.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CTXR since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CTXR analysts setting a high price target of $8.00 and a low target of $4.00, the average target price over the next 12 months is $5.33. Based on these targets, CTXR could surge 952.63% to reach the target high and rise by 426.32% to reach the target low. Reaching the average price target will result in a growth of 601.32% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded CTXR stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.